Investor Presentaiton
Investor presentation
First three months of 2017
Slide 68
VictozaⓇ statistically significantly reduced the risk of major
adverse cardiovascular events in the LEADER trial
13% reduction in 3-point MACE
with Victoza® compared with placebo
VictozaⓇ
Placebo
Patients¹ with an
event (%)
20
Hazard ratio = 0.87
95% CI (0.78;0.97)
p<0.001 for non-inferiority
p=0.011 for superiority
15
10
5
18
24
0 6 12
30 36 42 48
Time from randomisation (months)
¹Inclusion criteria: Adults above 50 years with type 2 diabetes and established CV disease, above 60
years with multiple CV factors, HbA1c ≥ 7.0%
MACE: major adverse cardiovascular events; 3-point MACE comprises cardiovascular death, non-fatal
myocardial infarction and non-fatal stroke; CI: two-sided confidence interval
changing
diabetes®
Key results
• Superiority of VictozaⓇ vs placebo was confirmed for time to
first MACE in people with type 2 diabetes at high CV risk
• VictozaⓇ reduced the MACE risk by 13%, driven by 22%
reduction in CV mortality, 12% reduction in non-fatal
myocardial infarctions and 11% reduction in non-fatal
stroke, compared with placebo when added to standard of
care
• VictozaⓇ reduced all-cause mortality by 15% respectively,
compared with placebo when added to standard of care
• The result was consistent across sensitivity analyses
54
•
VictozaⓇ appeared to have a safe and well tolerated profile,
generally consistent with previous studies for VictozaⓇ®
CV: Cardiovascular
novo nordiskView entire presentation